TNXP - トニックス・ファ―マシュ―ティカルズ （Tonix Pharmaceuticals Holding Corp.） トニックス・ファ―マシュ―ティカルズTNXPのチャート
TNXPの企業情報
| symbol | TNXP |
|---|---|
| 会社名 | Tonix Pharmaceuticals Holding Corp （トニックス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 トニックス・ファーマシューティカル・ホールディング（Tonix Pharmaceuticals Holding Corp）（旧名：タマンダレ・エクスプロレーションズ（Tamandare Explorations Inc.））は中枢神経系（CNS）疾患用の新薬開発に従事する専門製薬会社。同社のプロジェクトは開発段階にあり、製品はまた販売されていない。同社の主力薬品候補「TNX-102」はシクロベンザプリンの最適化された新剤形である。「TNX-102」は線維筋痛症（FM）を管理するために開発されている。同社は対象となる適応症或いは新しい治療用途に最適化された製品の開発を目的でこれらの薬剤の新しい製剤を作成する。同社のほかの薬品候補「TNX-105」は心的外傷後ストレス障害（PTSD）の症状を治療するシクロベンザプリンの新剤形である。シクロベンザプリンは米国食品医薬品局（FDA）によって承認・処方された、所定２種類の筋弛緩剤である「Flexeril」と「Amrix」の医薬品有効成分である。 トニックス・ファ―マシュ―ティカルズは米国の医薬品会社。中枢神経疾患の治療薬の開発を手掛ける。線維筋痛症および心的外傷後ストレス障害の治療に向けたシクロベンザブリン含有TNX-102舌下錠(TNX-102 SL)、反復性緊張型頭痛用治療薬TNX-201、アルコ―ル依存症治療薬TNX-301を開発中。 Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL1, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the third quarter of 20212 and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix's lead vaccine candidate, TNX-18003, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix reported positive efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-8013, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox. |
| 本社所在地 | 509 Madison Avenue Suite 306 New York NY 10022 USA |
| 代表者氏名 | Seth Lederman セス・レデルマン |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 212-980-9155 |
| 設立年月日 | 39387 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 28人 |
| url | www.tonixpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/tnxp |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -24.44900 |
| 終値（lastsale） | 0.5951 |
| 時価総額（marketcap） | 5661294.0131 |
| 時価総額 | 時価総額（百万ドル） 5.23225 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -11.44675 |
| 当期純利益 | 当期純利益（百万ドル） -24.30100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Tonix Pharmaceuticals Holding Corp revenues was not reported. Net loss increased 32% to $13M. Higher net loss reflects Research and development increase of 59% to $9.2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.92 to -$1.61. |
TNXPのテクニカル分析
TNXPのニュース
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Is Down -95.20% So Far This Year: What Will Happen Next? 2022/10/04 13:00:00 Stocks Register
The trading price of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) closed higher on Monday, October 03, closing at $0.55, 2.94% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $0.5435 and $0.62. In examining the 52-week price action we see that the stock hit a … Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Is Down -95.20% So Far This Year: What Will Happen Next? Read More »
Tonix stock rises on FDA nod to start trial of TNX-601 for depression 2022/10/03 11:47:07 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) cleared Tonix Pharmaceuticals'' (TNXP) application seeking to start a phase 2 of TNX-601 ER to treat major depressive disorder…
Analyze Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Before Investing. 2022/09/27 15:00:00 Stocks Register
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) price closed lower on Monday, September 26, dropping -3.62% below its previous close. A look at the daily price movement shows that the last close reads $0.55, with intraday deals fluctuated between $0.5215 and $0.57. The company’s 5Y monthly beta was ticking 1.53. Taking into account the 52-week price action … Analyze Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Before Investing. Read More »
Tonix Pharmaceuticals Holding Corp. (TNXP) did well last session? 2022/09/26 15:40:00 US Post News
In Friday’s session, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) marked $0.55 per share, down from $0.57 in the previous session. While Tonix Pharmaceuticals Holding Corp. has underperformed by -3.34%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TNXP fell by -97.25%, with highs and lows ranging from […]
Monkeypox Vaccine Market May See Big Move : Chimerix, TapImmune, Nanotherapeutics 2022/09/26 11:15:00 SBWire
New Jersey, NJ -- ( SBWIRE ) -- 09/26/2022 -- HTF MI introduces new research on Global Monkeypox Vaccine covering the micro level of analysis by competitors and key business segments. The Global Monkeypox Vaccine explores a comprehensive study on various segments like opportunities, size, development, innovation, sales, and overall growth of major players. The research is carried out on primary and secondary statistics sources and it consists of both qualitative and quantitative detailing. Some of the major key players profiled in the study are Emergent BioSolutions Inc. (United States), Wyeth Laboratories, Inc. (United States), Bavarian Nordic (Denmark), Sanofi Pasteur Biologics LLC. (United States), Chimerix (United States), Nanotherapeutics (United States), SIGA Technologies (United States), TapImmune (United States), Tonix Pharmaceuticals Holding (United States) and CEL-SCI (United States). Acquire Sample Report + All Related Table and Graphs@: https://www.htfmarketreport.com/sample-report/4151437-global-monkeypox-vaccine-market-1 Monkeypox is a viral zoonotic complaint that occurs primarily in tropical rainforest areas of central and West Africa and is sometimes exported to other regions.
Thinking about buying stock in VEON, Nio, Transocean, Clover Health Investments, or Tonix Pharmaceuticals? 2022/03/07 15:50:00 Benzinga
NEW YORK , March 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VEON, NIO, RIG, CLOV, and TNXP. … Full story available on Benzinga.com
Tonix Pharma Collaborates With Massachusetts General Hospital For TNX-1900 In Binge Eating Disorder 2022/03/07 15:22:02 Benzinga
Full story available on Benzinga.com
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating Disorder 2022/03/07 12:00:00 ForexTV
An Investigator Initiated Phase 2 Clinical Trial of TNX-1900 In Patients with Binge Eating Disorder Planned for Second Half 2022 Binge Eating Disorder is Estimated to Affect 2.8 Million American Adults1-3 Expands Uses of Tonix’s Proprietary Potentiated Oxytocin for Intranasal Administration to a Potential New Indication CHATHAM, N.J., March 07, 2022 (GLOBE NEWSWIRE) — Tonix … The post Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating Disorder appeared first on ForexTV .
Why Tonix Pharmaceuticals Is Down 19% Today 2022/03/04 20:54:01 The Motley Fool
Buyers are unwinding their trades in a big way, following through on the profit-taking they initiated yesterday.
Thinking about buying stock in VEON, E-Home Household Service, Tonix Pharmaceuticals, American Airlines, or Ocugen? 2022/03/04 16:15:00 Benzinga
NEW YORK , March 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VEON, EJH, TNXP, AAL, and OCGN. … Full story available on Benzinga.com
Is Tonix Pharmaceuticals About To Breakdown? 2021/04/20 13:41:50 Benzinga
There is a good chance Tonix Pharmaceuticals (NASDAQ: TNXP ) breaks the support at $1 and moves lower. There's support at this level because it's important psychologically. Many investors like to place their orders at nice round levels and that’s the case here. When TNXP fell to $1 in early March, a rally followed. But that may … Full story available on Benzinga.com
Tonix Pharma Stock Is Trading Higher On Expanding COVID-19 Candidate Portfolio With Sangivamycin Licensing Pact 2021/04/19 11:52:04 Benzinga
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) and privately-held OyaGen Inc have entered into an exclusive worldwide licensing agreement for TNX-3500 (sangivamycin, formerly OYA1) for the treatment of COVID-19 and potentially other viral disorders. Under the terms of the agreement, Tonix will conduct further studies to test the safety and efficacy of TNX-3500 in treating COVID-19. The financial details of the deal were … Full story available on Benzinga.com
worth buying post Earnings results? NASDAQ:TNXP NASDAQ:CUE NASDAQ:SMTC NASDAQ:HHR and #Covid-19 (#Coronavirus) impact 2021/03/20 19:14:00 Stock Market Daily
Earnings, Analyst opinion and estimate and latest Covid-19 (Coronavirus) impact on these hot stocks to invest
Positive Phase 3 Efficacy Data Bolsters Tonix Pharmaceuticals' Expectations For Phase 3 Confirmatory Trial In Fibromyalgia 2021/03/19 11:58:01 Benzinga
The following article is sponsored by the clinical communications unit of Redington, Inc. which is paid by Tonix Pharmaceuticals Holding Corp. to provide investor communications services. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Clinical-stage biopharmaceutical company Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) announced late last year positive results for the first of two pivotal Phase 3 studies of its lead fibromyalgia drug candidate, TNX-102 SL. The company reported that the results from its Phase 3 RELIEF study revealed TNX-102 SL provided statistically significant daily pain reduction over placebo while also being well-tolerated by participants in the study. “We are delighted with the results of our first positive Phase 3 study of TNX-102 SL for the management of fibromyalgia,” said Tonix Pharmaceuticals CEO, Dr. Seth Lederman. “RELIEF is the first of two studies that are required for approval by the U.S.
NewtoTheStreet's Newsmax Sunday 930AM EST Lineup Features Tonix Pharmaceuticals Holding Corp., Nextech AR, Winston Gold and NativeCoin - Stocks News Feed 2021/02/13 20:39:00 Stocks News Feed
NEW YORK, NY / ACCESSWIRE / February 13, 2021 / New To The Street will broadcast Show 151 Sunday 930AM EST on NEWSMAX T.V., and on FOX Business Monday evening 1030PM PST. The show will feature Doctor Seth Lederman President and co-founder Tonix Pharma, a research driven biotechnology company. Tonix is working on a 1… Read More »NewtoTheStreet’s Newsmax Sunday 930AM EST Lineup Features Tonix Pharmaceuticals Holding Corp., Nextech AR, Winston Gold and NativeCoin